person · Reporting owner

Silbermann Susan Michele

Disclosed activity across 3 companies

Tapewire entity: 94133
SEC CIK: 0001887214

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
HilleVax, Inc.HLVX · Entity 75097	Director	August 19, 2022	August 23, 2022
LianBioLIAN · Entity 9881	Director	February 15, 2024	February 20, 2024

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

HilleVax, Inc.

Report date August 19, 2022 · Filed August 23, 2022

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $12.38 · Expires 2032-08-18	Direct	25,000	Reported balance After 2022-08-19 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2022-08-19 · Grant · Acquired 25,000 · Balance 25,000 F1: The options shall vest on the first anniversary of the date of grant, subject to reporting person's continuing in service on the registrant's board of directors through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: The options shall vest on the first anniversary of the date of grant, subject to reporting person's continuing in service on the registrant's board of directors through such vesting date.

LianBio

Report date February 15, 2024 · Filed February 20, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	17,082	Ending reported balance After 2024-02-15 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2024-02-15 · Exercise / conversion · Acquired 36,300 · Balance 36,300 Row 2 · 2024-02-15 · Tax withholding · Disposed 19,218 · Balance 17,082
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.52 · Expires 2032-06-23	Direct	0	Reported balance After 2024-02-15 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-02-15 · Exercise / conversion · Disposed 36,300 · Balance 0 F1: The shares underlying the option became exercisable in full on June 23, 2023.

Filing footnotes · ownership attribution and instrument terms

F1: The shares underlying the option became exercisable in full on June 23, 2023.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Keenova Therapeutics plc

Report date November 14, 2023 · Filed November 16, 2023

Section 16 reporting ended · disclosed 2023-11-16. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	Direct	0	Reported balance After 2023-11-14 transaction · row 1 1 source row Row 1 · 2023-11-14 · Disposition to issuer · Disposed 23,122 · Balance 0 F1: On August 28, 2023, Mallinckrodt plc (the "Company") and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On September 20, 2023, the Company's directors presented a petition before the High Court of Ireland (the "Irish High Court") seeking the appointment of an examiner (the "Examiner") to the Company, thereby commencing examinership proceedings with respect to the Company in Ireland. F2: On October 10, 2023, the Bankruptcy Court entered an order confirming the First Amended Prepackaged Joint Chapter 11 Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates (as may be amended or supplemented from time to time in accordance with its terms, the "Plan"). On November 10, 2023, the Irish High Court made an order confirming a scheme of arrangement proposed by the Examiner that is based on and consistent in all respects with the Plan (the "Scheme"). On November 14, 2023 (the "Effective Date"), the Plan and the Scheme became effective and the Company emerged from bankruptcy. F3: On the Effective Date, all of the Company's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such Ordinary Shares, were cancelled and extinguished pursuant to the Plan and the Scheme. In connection with emergence, the reporting person ceased to be a Section 16 reporting person. This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.

Filing footnotes · ownership attribution and instrument terms

F1: On August 28, 2023, Mallinckrodt plc (the "Company") and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On September 20, 2023, the Company's directors presented a petition before the High Court of Ireland (the "Irish High Court") seeking the appointment of an examiner (the "Examiner") to the Company, thereby commencing examinership proceedings with respect to the Company in Ireland.

F2: On October 10, 2023, the Bankruptcy Court entered an order confirming the First Amended Prepackaged Joint Chapter 11 Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates (as may be amended or supplemented from time to time in accordance with its terms, the "Plan"). On November 10, 2023, the Irish High Court made an order confirming a scheme of arrangement proposed by the Examiner that is based on and consistent in all respects with the Plan (the "Scheme"). On November 14, 2023 (the "Effective Date"), the Plan and the Scheme became effective and the Company emerged from bankruptcy.

F3: On the Effective Date, all of the Company's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such Ordinary Shares, were cancelled and extinguished pursuant to the Plan and the Scheme. In connection with emergence, the reporting person ceased to be a Section 16 reporting person. This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 15, 2024 Filed Feb 20, 2024 21:10 UTC	LianBio LIAN · Entity 9881	Exercise / conversionStock Option (Right to Buy) · Derivative	36,300	$0.00 Strike: $2.52	$0.00	Disclosure SEC source: 0001831283-24-000010 · wk-form4_1708463411.xml · derivative · entry 3 Silbermann Susan Michele · CIK 0001887214 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 36,300 shares Expires 2032-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying the option became exercisable in full on June 23, 2023. Read SEC document
February 15, 2024 Filed Feb 20, 2024 21:10 UTC	LianBio LIAN · Entity 9881	Tax withholdingOrdinary Shares	19,218	$4.76	$91,477.68	Disclosure SEC source: 0001831283-24-000010 · wk-form4_1708463411.xml · nonDerivative · entry 2 Silbermann Susan Michele · CIK 0001887214 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,082 Read SEC document
February 15, 2024 Filed Feb 20, 2024 21:10 UTC	LianBio LIAN · Entity 9881	Exercise / conversionOrdinary Shares	36,300	$2.52	$91,476.00	Disclosure SEC source: 0001831283-24-000010 · wk-form4_1708463411.xml · nonDerivative · entry 1 Silbermann Susan Michele · CIK 0001887214 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 14, 2023 Filed Nov 16, 2023 21:13 UTC	Keenova Therapeutics plc MNKTQ · Entity 28960	Disposition to issuerOrdinary Shares	23,122	$0.00	$0.00	Disclosure SEC source: 0001104659-23-119112 · tm2330745-15_4seq1.xml · nonDerivative · entry 1 Silbermann Susan Michele · CIK 0001887214 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: On August 28, 2023, Mallinckrodt plc (the "Company") and certain of its subsidiaries voluntarily initiated proceedings under chapter 11 of title 11 of the United States Code in the U.S. Bankruptcy Court for the District of Delaware (the "Bankruptcy Court"). On September 20, 2023, the Company's directors presented a petition before the High Court of Ireland (the "Irish High Court") seeking the appointment of an examiner (the "Examiner") to the Company, thereby commencing examinership proceedings with respect to the Company in Ireland. F2 · kind: On October 10, 2023, the Bankruptcy Court entered an order confirming the First Amended Prepackaged Joint Chapter 11 Plan of Reorganization of Mallinckrodt Plc and Its Debtor Affiliates (as may be amended or supplemented from time to time in accordance with its terms, the "Plan"). On November 10, 2023, the Irish High Court made an order confirming a scheme of arrangement proposed by the Examiner that is based on and consistent in all respects with the Plan (the "Scheme"). On November 14, 2023 (the "Effective Date"), the Plan and the Scheme became effective and the Company emerged from bankruptcy. F3 · kind: On the Effective Date, all of the Company's previously outstanding ordinary shares (the "Ordinary Shares"), including options, warrants, rights, restricted stock units or other securities or agreements to acquire such Ordinary Shares, were cancelled and extinguished pursuant to the Plan and the Scheme. In connection with emergence, the reporting person ceased to be a Section 16 reporting person. This Form 4 constitutes a notice to the Issuer for purposes of Part V of the Companies Act 2014. Read SEC document
June 21, 2023 Filed Jun 23, 2023 20:20 UTC	LianBio LIAN · Entity 9881	GrantStock Option (Right to Buy) · Derivative	36,300	$0.00 Strike: $2.40	$0.00	Disclosure SEC source: 0001831283-23-000093 · wk-form4_1687551598.xml · derivative · entry 1 Silbermann Susan Michele · CIK 0001887214 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,300 Underlying: Ordinary Shares · 36,300 shares Expires 2033-06-21 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in full on June 21, 2024, the first anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date. Read SEC document
June 16, 2023 Filed Jun 29, 2023 22:51 UTC	Keenova Therapeutics plc MNK · Entity 28960	Disposition to issuerOrdinary Shares	26,277	Not disclosed	Not disclosed	Disclosure SEC source: 0001104659-23-076466 · tm2320181-7_4seq1.xml · nonDerivative · entry 2 Silbermann Susan Michele · CIK 0001887214 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,122 F1 · shares: The restricted stock units (the "RSUs") granted to the reporting person on January 3, 2023 were canceled by mutual agreement of the reporting person and Mallinckrodt plc ("Mallinckrodt") in connection with the Board of Directors (the "Board") of Mallinckrodt's approval of changes to the compensation of non-employee members of the Board (such changes, the "Compensation Changes"). In connection with the Compensation Changes, and in consideration of the cancelation of the RSUs, the reporting person will receive (i) in the event of a bankruptcy filing, additional cash compensation for 2023 of $210,000 or (ii) in the absence of a bankruptcy filing, additional cash compensation for 2023 of $245,000. In either event, the amounts are to be prepaid pro rata on a quarterly basis and paid in arrears for the prior quarters of fiscal year 2023. F1 · price: The restricted stock units (the "RSUs") granted to the reporting person on January 3, 2023 were canceled by mutual agreement of the reporting person and Mallinckrodt plc ("Mallinckrodt") in connection with the Board of Directors (the "Board") of Mallinckrodt's approval of changes to the compensation of non-employee members of the Board (such changes, the "Compensation Changes"). In connection with the Compensation Changes, and in consideration of the cancelation of the RSUs, the reporting person will receive (i) in the event of a bankruptcy filing, additional cash compensation for 2023 of $210,000 or (ii) in the absence of a bankruptcy filing, additional cash compensation for 2023 of $245,000. In either event, the amounts are to be prepaid pro rata on a quarterly basis and paid in arrears for the prior quarters of fiscal year 2023. F1 · balance_after: The restricted stock units (the "RSUs") granted to the reporting person on January 3, 2023 were canceled by mutual agreement of the reporting person and Mallinckrodt plc ("Mallinckrodt") in connection with the Board of Directors (the "Board") of Mallinckrodt's approval of changes to the compensation of non-employee members of the Board (such changes, the "Compensation Changes"). In connection with the Compensation Changes, and in consideration of the cancelation of the RSUs, the reporting person will receive (i) in the event of a bankruptcy filing, additional cash compensation for 2023 of $210,000 or (ii) in the absence of a bankruptcy filing, additional cash compensation for 2023 of $245,000. In either event, the amounts are to be prepaid pro rata on a quarterly basis and paid in arrears for the prior quarters of fiscal year 2023. Read SEC document
June 16, 2023 Filed Jun 29, 2023 22:51 UTC	Keenova Therapeutics plc MNK · Entity 28960	Tax withholdingOrdinary Shares	3,154	$1.28	$4,037.12	Disclosure SEC source: 0001104659-23-076466 · tm2320181-7_4seq1.xml · nonDerivative · entry 1 Silbermann Susan Michele · CIK 0001887214 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 49,399 Read SEC document
January 03, 2023 Filed Jan 5, 2023 23:02 UTC	Keenova Therapeutics plc MNK · Entity 28960	GrantOrdinary Shares	26,277	$0.00	$0.00	Disclosure SEC source: 0001104659-23-001544 · tm231710-5_4seq1.xml · nonDerivative · entry 1 Silbermann Susan Michele · CIK 0001887214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,553 F1 · shares: The reported ordinary shares represent restricted stock units ("RSUs"), which will be settled in an equal number of MNK ordinary shares and will vest ratably on each of the first two anniversaries of MNK's emergence from Chapter 11 proceedings on June 16, 2022. F2 · balance_after: The reporting person has reported prior awards of RSUs in Table II of Form 4. The total reported in Column 5 includes the 26,277 newly awarded RSUs and 26,276 RSUs previously reported in Table II. Read SEC document
October 11, 2022 Filed Oct 12, 2022 12:33 UTC	Keenova Therapeutics plc MNKPF · Entity 28960	GrantRestricted Stock Units · Derivative	26,276	$0.00	$0.00	Disclosure SEC source: 0001104659-22-107932 · tm2228042-1_4seq1.xml · derivative · entry 1 Silbermann Susan Michele · CIK 0001887214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,276 Underlying: Ordinary Shares · 26,276 shares Expires not disclosed F1 · derivative.exercise_price: On October 11, 2022, Susan Silbermann received a grant of 26,276 restricted stock units ("RSUs"), which grant of RSUs will vest ratably on each of the first two anniversaries of Mallinckrodt plc's emergence from Chapter 11 proceedings on June 16, 2022. F1 · derivative.exercise_date: On October 11, 2022, Susan Silbermann received a grant of 26,276 restricted stock units ("RSUs"), which grant of RSUs will vest ratably on each of the first two anniversaries of Mallinckrodt plc's emergence from Chapter 11 proceedings on June 16, 2022. F1 · derivative.expiration_date: On October 11, 2022, Susan Silbermann received a grant of 26,276 restricted stock units ("RSUs"), which grant of RSUs will vest ratably on each of the first two anniversaries of Mallinckrodt plc's emergence from Chapter 11 proceedings on June 16, 2022. Read SEC document
August 19, 2022 Filed Aug 23, 2022 16:35 UTC	HilleVax, Inc. HLVX · Entity 75097	GrantStock Option · Derivative	25,000	$0.00 Strike: $12.38	$0.00	Disclosure SEC source: 0000899243-22-029531 · doc4.xml · derivative · entry 1 Silbermann Susan Michele · CIK 0001887214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-08-18 F1 · derivative.exercise_date: The options shall vest on the first anniversary of the date of grant, subject to reporting person's continuing in service on the registrant's board of directors through such vesting date. Read SEC document
June 23, 2022 Filed Jun 27, 2022 20:17 UTC	LianBio LIAN · Entity 9881	GrantStock Option (Right to Buy) · Derivative	36,300	$0.00 Strike: $2.52	$0.00	Disclosure SEC source: 0001831283-22-000049 · wf-form4_165636102658025.xml · derivative · entry 1 Silbermann Susan Michele · CIK 0001887214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,300 Underlying: Ordinary Shares · 36,300 shares Expires 2032-06-23 F1 · derivative.exercise_date: The shares underlying the option shall vest and become exercisable in full on June 23, 2023, the first anniversary of the grant date, subject to the Reporting Person providing continuous service to the Issuer through such date. Read SEC document
October 31, 2021 Filed Nov 1, 2021 23:24 UTC	LianBio LIAN · Entity 9881	GrantStock Option (Right to Buy) · Derivative	72,600	$0.00 Strike: $16.00	$0.00	Disclosure SEC source: 0000899243-21-042219 · doc4.xml · derivative · entry 1 Silbermann Susan Michele · CIK 0001887214 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,600 Underlying: Ordinary Shares · 72,600 shares Expires 2031-10-31 F1 · derivative.exercise_date: 1/36 of the shares underlying the option vested and became exercisable on October 31, 2021; the remainder shall vest and become exercisable in 35 equal monthly installments such that the option shall be fully vested on October 31, 2024, subject to the Reporting Person providing continuous service to the Issuer on each such date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.